Tazobactam

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
목요일, 2월 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Baxter Reports Third-Quarter 2023 Results

Retrieved on: 
목요일, 11월 2, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, General Health, Health, Medical Devices, Health Technology, Baxter, Warburg Pincus, Tazobactam, BVLOS drone medical delivery trials in India, Piperacillin, Growth, EPS, Risk, BPS, Advent International, Medicine, Breakout Labs, EMR, Eye, Patient, Peritoneal dialysis, CDT, Pharmaceutical industry, Cassette tape, Fine chemical, Hemodialysis, Medication

Under the terms of the definitive agreement, Baxter received total proceeds of $4.25 billion, subject to adjustment for specified items.

Key Points: 
  • Under the terms of the definitive agreement, Baxter received total proceeds of $4.25 billion, subject to adjustment for specified items.
  • Baxter currently expects the Kidney Care spinoff to occur by July 2024 or earlier, subject to the satisfaction of customary conditions.
  • Baxter expects sales growth from continuing operations of 1% to 2% on a reported basis and approximately 1% on a constant currency basis.
  • A webcast of Baxter’s third-quarter 2023 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on Nov. 2, 2023.

Baxter Reports First-Quarter 2023 Results

Retrieved on: 
목요일, 4월 27, 2023
Biotechnology, Managed Care, Medical Supplies, Surgery, Health, Medical Devices, Hospitals, Fitness & Nutrition, Galaxy, DNA, ALF, Agility, Noise, Piperacillin, Fort Robinson breakout, Pump, Baxter, COVID-19, Thrombin, IQ, GAAP, Baxter International, U.S. FDA, Tazobactam, Acute liver failure, Information International, Inc., Hospital, Patient, Generally Accepted Accounting Principles (United States), Injection, Novum, Liver, Growth, CDT, SYR, NYSE, LVP, Cryptocurrency, Fine chemical, Pharmaceutical industry, Management, Security (finance)

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
  • On an adjusted basis, net income attributable to Baxter totaled $297 million, or $0.59 per diluted share, a 37% decrease.
  • Baxter expects to report quarterly performance in line with the new operating model beginning in the second half of 2023.
  • Among recent corporate responsibility highlights, Baxter and the Baxter International Foundation advanced support for disaster relief in response to February’s devastating earthquake in Turkey and Syria.

Baxter Launches Zosyn Premix in US

Retrieved on: 
화요일, 4월 4, 2023
Medical Supplies, Health, Hospitals, Other Health, Managed Care, Pharmaceutical, Biotechnology, Baxter, Piperacillin, Baxter International, Tazobactam, Information International, Inc., Galaxy, Patient, NYSE, Patient safety, Injection, Pharmaceutical industry, Medication

Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.

Key Points: 
  • Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.
  • “Zosyn premix is an important addition to Baxter’s portfolio of valuable anti-infective medications that help treat some of the most pressing healthcare needs facing patients today,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter.
  • Baxter will sell Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100mL presentations.
  • Like other medications in Baxter’s premix portfolio, Zosyn premix uses Baxter’s proprietary Galaxy container technology.

Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority

Retrieved on: 
수요일, 10월 5, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, European Medicines Agency, Robert Wood Johnson Medical School, Union, LinkedIn, Urinary tract infection, Therapy, Infection, Review, EMA, Bacterial pneumonia, Carbapenem, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Investor, Standard of care, MPH, Division, Piperacillin/tazobactam, UTI, Partnership, Food, Company, Marketing, MD, Esbly, Pyelonephritis, Adult, Cutis, Cutis marmorata telangiectatica congenita, American Medical Association, Journal, United Kingdom, Rutgers University, FDA, Tazobactam, Data analysis, ESBL, Pharmaceutical industry, EU

The publication represents the first full analysis of the completed Phase 3 program, which showed that cefepime/enmetazobactam met criteria for non-inferiority and superiority compared to piperacillin/tazobactam in the primary outcome of clinical cure and microbiological eradication.

Key Points: 
  • The publication represents the first full analysis of the completed Phase 3 program, which showed that cefepime/enmetazobactam met criteria for non-inferiority and superiority compared to piperacillin/tazobactam in the primary outcome of clinical cure and microbiological eradication.
  • Cefepime/enmetazobactam is a novel -lactam/-lactamase inhibitor combination for the treatment of resistant gram-negative infections mediated by Extended Spectrum Beta-Lactamases (ESBLs).
  • Based on the positive data readout, Allecra expects to submit for marketing approval in the U.S. and EU.
  • Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms.

Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

Retrieved on: 
수요일, 3월 23, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, MSD, MRK, NYSE, Vaccine, Research, SEC, Medicine, AstraZeneca, Twitter, Thomas Jefferson University, Cardiology, Â, MRL, University, Pembrolizumab, Security (finance), Population, Johns Hopkins University, Chicago (franchise), U.S. Securities and Exchange Commission, Animal, GCD, Streptococcus pneumoniae, Eisai, Cancer, Life, Patent, Merck & Co., Penn, Conjugate vaccine, Pennsylvania State University, Coronavirus, Tazobactam, Instagram, Patient, LinkedIn, Internal medicine, Leadership, HPV, Retirement, Private Securities Litigation Reform Act, COVID-19, News, YouTube, HIV, Infection, Pharmaceutical industry, Bayer, Merck, Facebook

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Roy D. Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Roy D. Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July.
  • It has been a privilege to have led the global clinical development organization during my tenure at Merck, said Dr. Baynes.
  • Dr. Baynes will be succeeded by Dr. Eliav Barr, senior vice president, Global Clinical Development.
  • I am honored to assume the role as head of Mercks industry-leading clinical development organization, said Dr. Barr.

Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

Retrieved on: 
수요일, 9월 16, 2020
Articles, Branches of biology, Beta-lactam antibiotics, Drugs, Ceftolozane/tazobactam, Beta-lactamase inhibitors, Tazobactam, Beta-lactamase, Antimicrobial resistance, DNA sequencing, Pseudomonas aeruginosa, Karen Bush

To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.

Key Points: 
  • To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.
  • Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam.
  • The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.
  • The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing.

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

Retrieved on: 
화요일, 2월 25, 2020
Medical specialties, Medicine, Health, Infectious diseases, Penicillins, Beta-lactamase inhibitors, Diketopiperazines, Piperacillin, Wyeth, Tazobactam, Hospital-acquired infection, Urinary tract infection

Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).

Key Points: 
  • Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).
  • Treatment discontinuations were seen at comparable levels in 5.2% and 4.0% in EXBLIFEP and piperacillin-tazobactam respectively.
  • HAP is the second most common nosocomial infection (after urinary tract infections) and accounts for 1520% of the total.
  • Allecra is supported by Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMed Partners.

Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit

Retrieved on: 
금요일, 8월 2, 2019
Bacteria, Chemical compounds, Organic compounds, Gram-negative bacteria, Beta-lactamase inhibitors, Antibiotics, Beta-lactam antibiotics, Antibiotic-resistant bacteria, Pseudomonas aeruginosa, Acinetobacter baumannii, Ceftolozane/tazobactam, Tazobactam

The new CE-IVD Accelerate PhenoTest BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, andtrimethoprim-sulfamethoxazole for A. baumannii bacteria.

Key Points: 
  • The new CE-IVD Accelerate PhenoTest BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, andtrimethoprim-sulfamethoxazole for A. baumannii bacteria.
  • The US-IVD Accelerate PhenoTest BC kit (catalog: 10101018) received clearance for in vitro diagnostic use in February of 2017.
  • The Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections.
  • The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
    For more information about the company, its products and technology, or publications, visit axdx.com .

Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)

Retrieved on: 
월요일, 7월 29, 2019
Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Health, Pneumonia, Infectious diseases, Beta-lactam antibiotics, Hospital-acquired pneumonia, Beta-lactamase inhibitors, Healthcare-associated infections, Ceftolozane/tazobactam, Tazobactam, Antibiotic

Supplemental marketing authorization applications for ZERBAXA for the treatment of nosocomial pneumonia, including VAP, are also under regulatory review in other countries, including Canada and Japan.

Key Points: 
  • Supplemental marketing authorization applications for ZERBAXA for the treatment of nosocomial pneumonia, including VAP, are also under regulatory review in other countries, including Canada and Japan.
  • ZERBAXA is an antibacterial combination product for intravenous infusion consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium.
  • This milestone reflects the valued contributions of all the health care professionals and patients involved in the pivotal ASPECT-NP trial.
  • According to a recent publication, ventilated patients with hospital-acquired bacterial pneumonia (HABP) have a higher rate of mortality (39%) than those with ventilator-associated bacterial pneumonia (VABP) (27%).